Artelo Biosciences Announces Reverse Stock Split

Artelo Biosciences (ARTL) reported that ART27.13, a dual cannabinoid receptor agonist, matched semaglutide's weight loss in an obesity model and showed enhanced effects when combined. ART27.13 reduced body weight by 20% alone and 40% with semaglutide, primarily through fat loss. The company plans to explore partnering opportunities for metabolic disease treatments.

Artelo Biosciences (ARTL) reported that its drug ART27.13 achieved 20% weight loss in obese mice, matching semaglutide's results. Combined with semaglutide, weight loss doubled to 40%. ART27.13 showed no effect in lean mice, suggesting potential as an obesity treatment. The company plans to explore partnerships based on these findings.

HSBC Holdings repurchased 590,000 shares on 21 September 2026, totaling US$827.1 million since the program began on 5 August 2026. The buyback, executed in the UK and Hong Kong, aims to enhance earnings per share and shareholder value, according to the company.

Jeld-Wen Holding Inc. is negotiating with creditors for an amend-and-extend deal, potentially including new capital from unsecured creditors to gain secured status. First-lien lenders can roll positions or accept repayment at a discount. The company reported a 0.7% revenue decline and a net loss of $31.5 million in Q2, with total debt of $1.25 billion. Unsecured debt prices have risen, reflecting investor interest.

Eli Lilly (LLY) broke ground on a $6.5B Houston facility to manufacture active pharmaceutical ingredients, including Foundayo (orforglipron), a GLP-1 drug for weight management. The site, part of Lilly's $50B U.S. investment, will create 600+ jobs and is supported by a $12.5M workforce training initiative with San Jacinto College. Foundayo is under regulatory review in over 40 countries, with global rollout targeted for 2027.

Sun Life Financial Inc. (SLF) announced plans to redeem $500 million in Series 2021-1 Subordinated Unsecured 2.46% Fixed/Floating Debentures on November 18, 2026. The redemption will be funded from existing cash and liquid assets, with holders receiving the principal amount plus accrued interest. After redemption, interest will cease to accrue, and holders will not retain any rights.